CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
0 ppm F +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04763044
NCT04763044Phase 4Completed
CompareCT.gov

Evaluation of the Fluoride Dose Response of MFP Dentifrice Using In Situ Caries Model

Procter and Gamble·interventional·Posted Feb 21, 2021·Updated Jul 19, 2022

In Brief

A Phase 4 clinical trial evaluating 0 ppm F, 250 ppm F as MFP, and 3 other interventions for Caries. Completed, enrolled 15 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate the fluoride dose response of different dentifrice fluoride concentrations - 0, 250, 1100 and 2800 ppm fluoride as sodium monofluorophosphate (MFP) and a fifth leg of 1100 ppm Stannous Fluoride (SnF2) using an in situ caries model.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCaries
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedFeb 21, 2021
Enrollment StartMar 1, 2021
Primary CompletionJul 21, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 5.4 years ago

Interventions

0 ppm Fdrug

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

250 ppm F as MFPdrug

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

1100 ppm as MFPdrug

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

2800 ppm F as MFPdrug

Each subject will be randomly assigned to this treatment during one of the four periods for this crossover study.

1100 ppm SnF2drug

Each subject will be assigned to this treatment during the fifth period for this crossover study.